Lung Cancer Screening: A Multilevel Intervention
The study will develop and test the feasibility of the Lung Cancer Assessment of Risk and Education (LungCARE) intervention to increase discussions about lung cancer screening between patients and physicians. This intervention will be designed to reach primary care patients and will be implemented at three levels of the healthcare structure: patient, physician, and system. The patient component includes a short lung cancer screening video and questions regarding screening preferences. Patients will receive immediate feedback in a report (patient report) that summarizes their lung cancer screening preferences and a handout summarizing the educational video. At the physician level, primary care physicians (PCPs) will receive a similar report (physician report), which will be delivered to them prior to the patient visit. The report contains additional information about documenting discussion related to risk, screening, and referrals in the electronic health record (EHR) system (system component). The investigators will develop the LungCARE intervention and have a comparison group that will receive usual care. Preliminary testing of LungCARE will occur via a randomized controlled trial (RCT) at the University of California, San Francisco, General Internal Medicine and Women's Health Primary Care clinics. The RCT will evaluate LungCARE among 50 PCPs and 120 high-risk current and former smoker patients. The investigators will determine whether the intervention is accepted by patients and physicians and whether patients who received LungCARE are more likely to discuss lung cancer screening with their physicians when compared to patients and physicians in the comparison group. The investigators will also determine whether the intervention affects knowledge of lung cancer and low-dose computed tomography (LDCT) screening, perception of risk, and worry about lung cancer in patients when compared to patients in the comparison group. The investigators expect their research to provide specific recommendations that will facilitate patient-physician discussions about LDCT screening and promote shared decision-making among patients and physicians.
Checked against the public recordLast updated Oct 23, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Screening
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- University of California, San Francisco
- Interventions being studied
- Behavioral: LungCARE
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * age 55-80 * smoked at least 30 pack-years in lifetime * if former smoker, quit smoking within the last 15 years * English speaker * no prior history of lung cancer * did not have a lung cancer screening test within the last year * PCP does not object to patient's participation * have a scheduled visit at University of California, San Francisco (UCSF) internal medicine clinics. Exclusion Criteria: * speaking a language other than English * has a history of lung cancer * had a lung cancer screening test within the last year * PCP objects to patient's participation.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of California, San FranciscoSan Francisco, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 23, 2020. Always confirm current availability with the study team.